Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Edema 2Brain Neoplasms 2Brain Edema 2Astrocytoma 2

Interventions

Paclitaxel 491Carboplatin 436Gemcitabine 394Docetaxel 386Cisplatin 361pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 222Dexamethasone 213Fluorouracil 212Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 161Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 140Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Corticotropin-Releasing Hormone × Clear all
NCT00088166 2014-08-13

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

Celtic Pharma Development Services

Phase 3 Completed
200 enrolled 17 charts
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

NCT00226655 2012-08-31

An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

Celtic Pharma Development Services

Phase 3 Completed
112 enrolled 8 charts
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡